An ambitious, multi-institutional clinical trial of low dose interleukin-2 (IL-2) in ALS has received funding from Motor Neuron Disease Association in the UK, the French government and the European Commission’s Horizon 2020 Program. The clinical trial, called Modifying Immune Response and Outcomes in Amyotrophic Lateral Sclerosis (MIROCALS), will examine whether low dose IL-2, an anti-inflammatory drug used at higher doses to treat cancer, will slow disease progression and exert beneficial effects in ALS (see March 2014 news). The trial will also include a comprehensive companion biomarker study to monitor drug effects and identify drug-responsive patient subgroups. The groundwork for the study, which is co-directed by Gilbert Bensimon, of University Hospital, Nimes, France and Nigel Leigh of Brighton and Sussex Medical School, UK, will begin in September 2015 with a pilot study in France, followed by recruitment for the main trial in 2016. Click here and here to read more.
disease-als topic-clinicalShare this: